



**Adzenys XR-ODT®  
Effective March 1, 2018**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Adzenys XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

**Coverage Guidelines**

1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) or narcolepsy **AND**
2. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Adderall XR® (amphetamine salts extended-release)

*Please note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.*

**Continuation of Therapy**

Reauthorization require documentation by prescriber that indicates a positive response to therapy.

**Limitations**

Initial and reauthorization approvals may be granted for up to 1 year

**Appendix**

Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of **both** a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic



heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

### **References**

1. Adzenys XR-ODT (amphetamine) [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC.; December 2017

### **Review History**

03/01/18 – Implemented (Adopted MH PDS)

04/17/19 – Reviewed P&T Mtg

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.